AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUL 17 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - The CD20 antigen, expressed only on B lineage cells before differentiation into plasma cells, produced a strong, specific, polyclonal immune response in mice, researchers in New York have found.
"Monoclonal antibodies to CD20 have been used successfully in the treatment of B-cell lymphomas," explained W.K. Roberts and colleagues at the Memorial Sloan-Kettering Cancer Center in New York City. "Vaccine therapy would have the advantage of generating a polyclonal response to the antigen in contrast to the monoclonal response of an infused antibody."
The investigators inoculated Balb/c mice with a vaccine consisting of human or mouse CD20 peptides conjugated to carrier proteins, and an OS21 adjuvant.
Enzyme-linked immunosorbent assay (ELISA) revealed that inoculation stimulated a high-titer, specific antibody response to several CD20 epitopes. Flow cytometry showed weak antibody binding to native cellular CD20. In some samples, outright death of CD20-expressing cells was caused by antibody-mediated complement. Vaccination with the CD20 antigen also elicited production of interleukin 4 and interferon (gamma).
A 25% decrease in splenic B cells expressing CD19 (compared with control) occurred in mice that received the ...
Source: HighBeam Research, Conjugated CD20 vaccine elicits specific, polyclonal immune response...